27 September 2024 false No description of principal activity Taxfiler 2024.6 15983311business:PrivateLimitedCompanyLtd2024-09-272025-09-30 159833112024-09-26 159833112024-09-272025-09-30 15983311business:AuditExempt-NoAccountantsReport2024-09-272025-09-30 15983311business:FilletedAccounts2024-09-272025-09-30 159833112025-09-30 15983311business:Director12024-09-272025-09-30 15983311business:RegisteredOffice2024-09-272025-09-30 15983311core:WithinOneYear2025-09-30 15983311core:ShareCapitalcore:PreviouslyStatedAmount2025-09-30 15983311core:PreviouslyStatedAmount2025-09-30 15983311business:SmallEntities2024-09-272025-09-30 15983311countries:EnglandWales2024-09-272025-09-30 iso4217:GBP xbrli:pure
Company Registration No. 15983311 (England and Wales)
Strategic Clinical Trials Services Limited Unaudited accounts for the period from 27 September 2024 to 30 September 2025
Strategic Clinical Trials Services Limited Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Strategic Clinical Trials Services Limited Company Information for the period from 27 September 2024 to 30 September 2025
Director
Roshan Fakira
Company Number
15983311 (England and Wales)
Registered Office
21 Larkmead Astley Tyldesley Manchester Lancashire M29 7SU England
Accountants
Saccounts Limited 190 Cathedral Road Cardiff CF11 9JE
- 3 -
Strategic Clinical Trials Services Limited Statement of financial position as at 30 September 2025
2025 
Notes
£ 
Current assets
Debtors
4
17,062 
Cash at bank and in hand
15,720 
32,782 
Creditors: amounts falling due within one year
5
(32,779)
Net current assets
3 
Net assets
3 
Capital and reserves
Called up share capital
3 
Shareholders' funds
3 
For the period ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 7 January 2025 and were signed on its behalf by
Roshan Fakira Director Company Registration No. 15983311
- 4 -
Strategic Clinical Trials Services Limited Notes to the Accounts for the period from 27 September 2024 to 30 September 2025
1
Statutory information
Strategic Clinical Trials Services Limited is a private company, limited by shares, registered in England and Wales, registration number 15983311. The registered office is 21 Larkmead, Astley, Tyldesley, Manchester, Lancashire, M29 7SU, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
4
Debtors
2025 
£ 
Amounts falling due within one year
Trade debtors
17,062 
5
Creditors: amounts falling due within one year
2025 
£ 
Taxes and social security
7,661 
Loans from directors
19,471 
Accruals
5,647 
32,779 
6
Average number of employees
During the period the average number of employees was 0.
- 5 -